Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults
- 2015-11-30
- European Journal of Nutrition 56(2)
- Huicui Meng
- Zhaoyong Ba
- Yujin Lee
- Jiayu Peng
- Junli Lin
- J. Fleming
- E. Furumoto
- R. Roberts
- P. Kris-Etherton
- C. Rogers
- PubMed: 26621631
- DOI: 10.1007/s00394-015-1109-5
Abstract
Purpose: Probiotic bacteria modulate immune parameters and inflammatory outcomes. Emerging evidence demonstrates that the matrix used to deliver probiotics may influence the efficacy of probiotic interventions in vivo. The aims of the current study were to evaluate (1) the effect of one species, Bifidobacterium animalis subsp. lactis BB-12 at a dose of log10 ± 0.5 CFUs/day on immune responses in a randomized, partially blinded, 4-period crossover, free-living study, and (2) whether the immune response to BB-12 differed depending on the delivery matrix.
Methods: Healthy adults (n = 30) aged 18-40 years were recruited and received four treatments in a random order: (A) yogurt smoothie alone; smoothie with BB-12 added (B) before or (C) after yogurt fermentation, or (D) BB-12 given in capsule form. At baseline and after each 4-week treatment, peripheral blood mononuclear cells (PBMCs) were isolated, and functional and phenotypic marker expression was assessed.
Results: BB-12 interacted with peripheral myeloid cells via Toll-like receptor 2 (TLR-2). The percentage of CD14+HLA-DR+ cells in peripheral blood was increased in male participants by all yogurt-containing treatments compared to baseline (p = 0.0356). Participants who consumed yogurt smoothie with BB-12 added post-fermentation had significantly lower expression of TLR-2 on CD14+HLA-DR+ cells (p = 0.0186) and reduction in TNF-α secretion from BB-12- (p = 0.0490) or LPS-stimulated (p = 0.0387) PBMCs compared to baseline.
Conclusions: These findings not only demonstrate a potential anti-inflammatory effect of BB-12 in healthy adults, but also indicate that the delivery matrix influences the immunomodulatory properties of BB-12.
Keywords: BB-12; Delivery matrix; Inflammation; Probiotics; TNF-α.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Bifidobacterium animalis subsp. lactis | Reduced TLR-2 Expression on CD14+HLA-DR+ Cells | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Reduced TNF-α Secretion | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis B420 | Reduced Pro-inflammatory Cytokines TNF-α Levels | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis B420 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis BLC1 | Increased CD14+HLA-DR+ Cells in Peripheral Blood | Beneficial | Small |
| Bifidobacterium animalis subsp. lactis BLC1 | Reduced TLR-2 Expression on CD14+HLA-DR+ Cells | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis BLC1 | Reduced TNF-α Secretion | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis BS-01 | Increased CD14+HLA-DR+ Cells in Peripheral Blood | Beneficial | Small |
| Bifidobacterium animalis subsp. lactis BS-01 | Reduced Proinflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis BS-01 | Reduced TLR-2 Expression on CD14+HLA-DR+ Cells | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Increased CD14+HLA-DR+ Cells in Peripheral Blood | Beneficial | Small |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Reduced TLR-2 Expression on CD14+HLA-DR+ Cells | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Reduced TNF-α Secretion | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis VK2 | Increased CD14+HLA-DR+ Cell Percentage in Males | Neutral | Small |
| Bifidobacterium animalis subsp. lactis VK2 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis VK2 | Reduced TNF-α Secretion | Beneficial | Moderate |
| Bifidobacterium bifidum BB01 | Increased CD14+HLA-DR+ Cells in Peripheral Blood | Beneficial | Small |
| Bifidobacterium bifidum BB01 | Reduced Proinflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium bifidum BB01 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |
| Bifidobacterium bifidum/lactis Bb-02 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |
| Bifidobacterium bifidum/lactis Bb-02 | Reduced TNF-α Secretion | Beneficial | Moderate |
| Bifidobacterium lactis Bb-02 | Reduced Pro-inflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium lactis Bb-02 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |
| Bifidobacterium lactis BB-12 | Reduced Pro-inflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium lactis BB-12 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |
| Bifidobacterium lactis BL818 | Reduced Proinflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium lactis BLA80 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |
| Bifidobacterium lactis BLA80 | Reduced TNF-α Secretion | Beneficial | Moderate |
| Bifidobacterium lactis BLC-1 | Reduced Inflammatory Marker Protein Levels | Beneficial | Moderate |
| Bifidobacterium lactis BLC-1 | Reduced Pro-inflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium lactis HDS Bb-02 | Reduced Pro-inflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium lactis HDS Bb-02 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |
| Bifidobacterium lactis ISS Bif | Reduced Inflammatory Marker Protein Levels | Beneficial | Moderate |
| Bifidobacterium lactis ISS Bif | Reduced Pro-inflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium lactis UABla-12 | Reduced Pro-inflammatory Cytokine Secretion | Beneficial | Moderate |
| Bifidobacterium lactis UABla-12 | Reduced TLR-2 Expression on Monocytes | Beneficial | Moderate |